Citizens JMP raised the firm’s price target on Halozyme (HALO) to $78 from $73 and keeps an Outperform rating on the shares. Halozyme reported Q4 results above consensus expectations while reiterating guidance for 2025 and its longer-term 2026-2028 outlook, the analyst tells investors in a research note. Citizens JMP says it has confidence in the durability of multiple royalty streams well into the 2030s, with upside from current pipeline programs.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Buy Rating Affirmed: Halozyme’s Robust Growth and Strategic Positioning Drive Positive Outlook
- Halozyme price target raised to $72 from $70 at H.C. Wainwright
- Halozyme Therapeutics Achieves Record Revenue in 2024
- Positive Outlook and Strategic Growth: Brendan Smith’s Buy Rating on Halozyme
- Halozyme reports Q4 EPS $1.06, consensus $1.16